医学
肿瘤科
多发性骨髓瘤
癌症
内科学
外周血淋巴细胞
生物标志物
免疫系统
免疫学
CD28
衰老
白细胞介素2受体
免疫衰老
T细胞
生物
生物化学
作者
Geoffrey Fell,Ashley Rosko,Gregory A. Abel,Clark DuMontier,Kelly Higby,Anays Murillo,Donna Neuberg,Christin E. Burd,Andrew A. Lane
摘要
Older patients with cancer often receive treatment regimens based on their age without considering other objective factors that may influence outcomes. Assessment of frailty can identify older patients who are robust and therefore more likely to benefit from intensive treatment, or conversely, frail and might instead be offered alternative approaches. However, such assessment requires specialised training and dedicated clinical resources. Alternative quantitative biomarkers associated with frailty are lacking. Here, we asked if expression signatures of 74 immune cell, ageing, and senescence-related messenger RNAs in purified peripheral blood T cells could identify associations with clinical frailty in patients with haematological malignancies. We studied 69 patients between the ages of 36 and 92 years (median 76 years) with leukaemia, lymphoma, or multiple myeloma, across two institutions. Expression of four genes (aryl hydrocarbon receptor [AHR], CD27, CD28, and interleukin-2 receptor subunit alpha [IL2RA; CD25]) in T cells was associated with frailty, independent of age. An expression-based regression model had 76% sensitivity and 90% specificity to assign a patient as robust. These data identify measurable peripheral blood correlates of clinical frailty and suggest biomarkers for future prospective assessment.
科研通智能强力驱动
Strongly Powered by AbleSci AI